Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for debilitating fibrosing skin disorders
2009-012034-70Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Cutaneous fibrosing disorder, sponsored by Ghent University Hospital. Primary endpoint: Efficacy and safety of rituximab. Started Apr 2009; status: completed.
02
Drugs
rituximab
03
Conditions
Cutaneous fibrosing disorder
Beyond the preview
Go deeper on 2009-012034-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012034-70.